Incyte's Minjuvi Receives EC Approval for Lymphoma Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2025
0mins
Should l Buy INCY?
Incyte Corp's stock rose by 5.48% as it reached a 5-day high, reflecting positive momentum in the market.
This surge is attributed to the European Commission's approval of Incyte's Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for treating relapsed follicular lymphoma, marking a significant advancement in oncology and addressing critical treatment gaps. The Phase 3 inMIND trial demonstrated a median progression-free survival (PFS) of 22.4 months, significantly outperforming the control group, which indicates the therapy's potential to improve patient outcomes.
The approval of Minjuvi not only enhances Incyte's portfolio but also positions the company for further growth in the oncology market, fulfilling a substantial unmet need for patients with relapsed lymphoma.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to fall
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 102.990
Low
73.00
Averages
100.31
High
125.00
Current: 102.990
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
Mixed Close for US Stocks as Retail Sales Stagnate
- Retail Sales Weakness: US December retail sales were unchanged month-over-month, falling short of the +0.4% expectation, indicating weakness in consumer spending that could lead to a downward revision in Q4 GDP, thereby impacting market confidence and economic growth outlook.
- Employment Cost Index Decline: The US Q4 employment cost index rose by +0.7% quarter-over-quarter, below the expected +0.8%, marking the smallest increase in 4.5 years, suggesting easing labor cost pressures that may influence the Fed's monetary policy decisions.
- Mixed Market Performance: The Dow Jones Industrial Average reached a new all-time high, closing up +0.10%, while the S&P 500 and Nasdaq 100 indices fell by -0.33% and -0.56%, respectively, reflecting divergent market sentiment and uncertainty.
- Focus on Upcoming Economic Data: The market will closely monitor upcoming economic data, including January nonfarm payrolls and unemployment rate, which are expected to significantly influence future monetary policy and market trends.
See More
US Retail Sales Weakness Impacts Markets
- Retail Sales Stagnation: US retail sales for December were unchanged month-over-month, falling short of the +0.4% expectation, indicating weakness in consumer spending that could lead to a downward revision in Q4 GDP, thereby impacting overall economic growth forecasts.
- Employment Cost Index Decline: The Q4 employment cost index rose by 0.7% quarter-over-quarter, below the expected 0.8%, marking the smallest increase in 4.5 years, suggesting easing labor cost pressures that may influence Federal Reserve monetary policy decisions.
- Positive Earnings Outlook: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth is projected at 8.4%, reflecting strong corporate profitability that could support stock market performance.
- Market Focus on Economic Data: This week, the market will concentrate on upcoming economic data releases, including non-farm payrolls and CPI, which are expected to influence investor expectations regarding future interest rate policies and subsequently affect stock market volatility.
See More
Incyte Corporation Q4 2025 Earnings Call Highlights
- Sales Performance Exceeds Expectations: Incyte reported total revenues of $1.51 billion in Q4 2025, a 28% increase year-over-year, with annual revenues reaching $5.14 billion, reflecting strong performance in both core business and Jakafi sales, with expectations for continued growth in 2026.
- Core Business Growth Significant: The core business, excluding Jakafi, achieved $1.26 billion in sales in Q4, a 53% year-over-year increase, driven by Opzelura, NiktimVo, and Monjuvi, with projections for over 30% growth in 2026 and potential to reach $3 billion to $4 billion by 2030.
- Strong New Product Sales: Opzelura's net sales totaled $207 million in Q4, up 28%, with full-year sales at $678 million, and 2026 sales expected to reach $750 million to $790 million, indicating rapid growth in international markets.
- Increased R&D Spending: The company reported GAAP R&D expenses of $611 million for Q4, a 31% increase, reflecting ongoing investments in new products and clinical trials, with 2026 R&D and SG&A expenses projected to be $3.495 billion to $3.675 billion, demonstrating confidence in future growth.
See More
Analysis of Significant Stock Movements Among Companies
- Amentum Holdings Decline: Amentum Holdings' stock fell approximately 12% after fiscal Q1 revenue and adjusted EBITDA missed Wall Street analysts' consensus estimates, indicating market concerns over its financial performance and potential future financing capabilities.
- BP Suspends Buyback: BP Plc suspended its stock buyback program to strengthen its balance sheet, resulting in a 6% drop in its ADRs in the U.S., reflecting the company's cautious approach amid market volatility.
- ZoomInfo Downgrade: ZoomInfo Technologies forecasted first-quarter earnings per share between 25 to 27 cents, below analysts' expectations of 27 cents, leading to a 10% decline in its stock price, which may affect market confidence and investor sentiment.
- Ichor Holdings Surge: Ichor Holdings' shares soared 37% to a 52-week high due to strong demand driving a fourth-quarter earnings beat, highlighting the recovery potential in the semiconductor equipment market.
See More
FDA's Accelerated Approval Framework Drives Cancer Treatment Advances
- Clinical Survival Rate Improvement: A January 2026 analysis confirmed that drugs approved through the FDA's accelerated pathway improved progression-free survival in 65% of solid tumor indications, demonstrating significant clinical efficacy and driving clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types.
- Fast Track Designation: Oncolytics Biotech's cancer treatment pelareorep received FDA Fast Track designation for KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, achieving a 33% response rate in combination with standard chemotherapy, significantly higher than the 10% response rate with standard treatment, and a median survival of 27 months compared to 11.2 months with standard care.
- Substantial Market Potential: The second-line treatment market for KRAS-mutant microsatellite-stable colorectal cancer patients is estimated to be between $3 billion and $5 billion annually, with Oncolytics Biotech planning a controlled study to compare standard care versus standard care plus pelareorep, further validating its therapeutic advantage in this high-demand area.
- Team Expansion and Strategic Positioning: Oncolytics Biotech recently appointed two key executives to support its expansion plans, with CEO Jared Kelly emphasizing that the success of pelareorep in clinical trials will present significant market opportunities, particularly in cancer areas lacking effective treatment options.
See More
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
Mixed Close for US Stocks as Retail Sales Stagnate
- Retail Sales Weakness: US December retail sales were unchanged month-over-month, falling short of the +0.4% expectation, indicating weakness in consumer spending that could lead to a downward revision in Q4 GDP, thereby impacting market confidence and economic growth outlook.
- Employment Cost Index Decline: The US Q4 employment cost index rose by +0.7% quarter-over-quarter, below the expected +0.8%, marking the smallest increase in 4.5 years, suggesting easing labor cost pressures that may influence the Fed's monetary policy decisions.
- Mixed Market Performance: The Dow Jones Industrial Average reached a new all-time high, closing up +0.10%, while the S&P 500 and Nasdaq 100 indices fell by -0.33% and -0.56%, respectively, reflecting divergent market sentiment and uncertainty.
- Focus on Upcoming Economic Data: The market will closely monitor upcoming economic data, including January nonfarm payrolls and unemployment rate, which are expected to significantly influence future monetary policy and market trends.
See More
US Retail Sales Weakness Impacts Markets
- Retail Sales Stagnation: US retail sales for December were unchanged month-over-month, falling short of the +0.4% expectation, indicating weakness in consumer spending that could lead to a downward revision in Q4 GDP, thereby impacting overall economic growth forecasts.
- Employment Cost Index Decline: The Q4 employment cost index rose by 0.7% quarter-over-quarter, below the expected 0.8%, marking the smallest increase in 4.5 years, suggesting easing labor cost pressures that may influence Federal Reserve monetary policy decisions.
- Positive Earnings Outlook: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth is projected at 8.4%, reflecting strong corporate profitability that could support stock market performance.
- Market Focus on Economic Data: This week, the market will concentrate on upcoming economic data releases, including non-farm payrolls and CPI, which are expected to influence investor expectations regarding future interest rate policies and subsequently affect stock market volatility.
See More
Incyte Corporation Q4 2025 Earnings Call Highlights
- Sales Performance Exceeds Expectations: Incyte reported total revenues of $1.51 billion in Q4 2025, a 28% increase year-over-year, with annual revenues reaching $5.14 billion, reflecting strong performance in both core business and Jakafi sales, with expectations for continued growth in 2026.
- Core Business Growth Significant: The core business, excluding Jakafi, achieved $1.26 billion in sales in Q4, a 53% year-over-year increase, driven by Opzelura, NiktimVo, and Monjuvi, with projections for over 30% growth in 2026 and potential to reach $3 billion to $4 billion by 2030.
- Strong New Product Sales: Opzelura's net sales totaled $207 million in Q4, up 28%, with full-year sales at $678 million, and 2026 sales expected to reach $750 million to $790 million, indicating rapid growth in international markets.
- Increased R&D Spending: The company reported GAAP R&D expenses of $611 million for Q4, a 31% increase, reflecting ongoing investments in new products and clinical trials, with 2026 R&D and SG&A expenses projected to be $3.495 billion to $3.675 billion, demonstrating confidence in future growth.
See More
Analysis of Significant Stock Movements Among Companies
- Amentum Holdings Decline: Amentum Holdings' stock fell approximately 12% after fiscal Q1 revenue and adjusted EBITDA missed Wall Street analysts' consensus estimates, indicating market concerns over its financial performance and potential future financing capabilities.
- BP Suspends Buyback: BP Plc suspended its stock buyback program to strengthen its balance sheet, resulting in a 6% drop in its ADRs in the U.S., reflecting the company's cautious approach amid market volatility.
- ZoomInfo Downgrade: ZoomInfo Technologies forecasted first-quarter earnings per share between 25 to 27 cents, below analysts' expectations of 27 cents, leading to a 10% decline in its stock price, which may affect market confidence and investor sentiment.
- Ichor Holdings Surge: Ichor Holdings' shares soared 37% to a 52-week high due to strong demand driving a fourth-quarter earnings beat, highlighting the recovery potential in the semiconductor equipment market.
See More
